NCT05126277: An ongoing trial by Novartis Pharmaceuticals
This trial is ongoing. It must report results 2 years, 6 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05126277 |
|---|---|
| Title | A Randomized, Double-blind, Parallel Group, Placebo-controlled, Multicenter Phase 3 Trial to Evaluate Efficacy, Safety and Tolerability of Ianalumab on Top of Standard-of-care Therapy in Participants With Active Lupus Nephritis (SIRIUS-LN). |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | July 14, 2022 |
| Completion date | June 22, 2027 |
| Required reporting date | June 21, 2028, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |